PL3490565T3 - Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie - Google Patents
Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanieInfo
- Publication number
- PL3490565T3 PL3490565T3 PL17835338.9T PL17835338T PL3490565T3 PL 3490565 T3 PL3490565 T3 PL 3490565T3 PL 17835338 T PL17835338 T PL 17835338T PL 3490565 T3 PL3490565 T3 PL 3490565T3
- Authority
- PL
- Poland
- Prior art keywords
- chemokine receptor
- receptor modulators
- azetidine derivatives
- azetidine
- derivatives
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title 1
- 108050000299 Chemokine receptor Proteins 0.000 title 1
- 150000001539 azetidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368848P | 2016-07-29 | 2016-07-29 | |
| US201662426087P | 2016-11-23 | 2016-11-23 | |
| PCT/US2017/044369 WO2018022992A1 (en) | 2016-07-29 | 2017-07-28 | Chemokine receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3490565T3 true PL3490565T3 (pl) | 2022-09-26 |
Family
ID=61016874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17835338.9T PL3490565T3 (pl) | 2016-07-29 | 2017-07-28 | Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10179787B2 (pl) |
| EP (1) | EP3490565B1 (pl) |
| JP (1) | JP6985388B2 (pl) |
| KR (1) | KR102566924B1 (pl) |
| CN (1) | CN109789146B (pl) |
| AU (1) | AU2017302635B2 (pl) |
| CA (1) | CA3032133A1 (pl) |
| DK (1) | DK3490565T3 (pl) |
| ES (1) | ES2925564T3 (pl) |
| HU (1) | HUE059242T2 (pl) |
| IL (1) | IL264397B2 (pl) |
| MX (1) | MX394691B (pl) |
| NZ (1) | NZ750182A (pl) |
| PL (1) | PL3490565T3 (pl) |
| PT (1) | PT3490565T (pl) |
| RU (1) | RU2768827C2 (pl) |
| SG (1) | SG11201900561XA (pl) |
| TW (1) | TWI817929B (pl) |
| WO (1) | WO2018022992A1 (pl) |
| ZA (1) | ZA201900961B (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102000770B1 (ko) | 2011-12-01 | 2019-07-16 | 케모센트릭스, 인크. | Ｃｃｒ(4) 길항제로서의 치환된 아닐린 |
| PH12016500582B1 (en) | 2013-10-04 | 2023-06-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| JP6980649B2 (ja) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 |
| US10179787B2 (en) | 2016-07-29 | 2019-01-15 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
| AU2018360766B2 (en) * | 2017-11-06 | 2024-09-19 | Rapt Therapeutics, Inc. | Anticancer agents |
| HUE069276T2 (hu) | 2018-01-26 | 2025-02-28 | Rapt Therapeutics Inc | Kemokin receptor modulátorok és azok felhasználása |
| WO2019178329A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of Michigan | Compositions and methods for treating graves disease |
| WO2019228404A1 (zh) * | 2018-05-31 | 2019-12-05 | 信达生物制药(苏州)有限公司 | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 |
| KR102584855B1 (ko) * | 2018-06-26 | 2023-10-05 | 케이피씨 파마슈티컬스 인코포레이티드 | 벤즈이미다졸 유도체 및 idh1 억제제로서의 이의 용도 |
| SG11202101454PA (en) * | 2018-08-29 | 2021-03-30 | Chemocentryx Inc | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109796457B (zh) * | 2019-03-28 | 2020-03-06 | 苏州国匡医药科技有限公司 | 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用 |
| CN112062728A (zh) * | 2019-05-25 | 2020-12-11 | 上海鑫凯化学科技有限公司 | 一种3,5-二氯-6-乙基吡嗪甲酰胺的合成方法 |
| US12006318B2 (en) * | 2019-11-13 | 2024-06-11 | Rapt Therapeutics, Inc. | Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof |
| CA3163930A1 (en) * | 2019-12-09 | 2021-06-17 | Imago Biosciences, Inc. | Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms |
| CN111471025A (zh) * | 2020-03-26 | 2020-07-31 | 兰州康寓信生物科技有限公司 | 一种法匹拉韦中间体及法匹拉韦的合成方法 |
| CN111732572B (zh) * | 2020-07-31 | 2020-11-13 | 苏州国匡医药科技有限公司 | 一种手性抗肿瘤药物flx475及其中间体的制备方法 |
| CN115466244B (zh) * | 2021-06-10 | 2024-08-02 | 武汉伯瑞恒医药科技有限公司 | 趋化因子受体ccr4拮抗剂、其中间体、制备方法、药物组合物和应用 |
| EP4370506A1 (en) | 2021-12-30 | 2024-05-22 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| US12240837B2 (en) * | 2022-04-06 | 2025-03-04 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
| KR20250019039A (ko) | 2022-06-02 | 2025-02-07 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | 헤테로고리 화합물 ccr4 억제제 및 이의 용도 |
| WO2024222736A1 (zh) * | 2023-04-24 | 2024-10-31 | 浙江华海药业股份有限公司 | 趋化因子受体调节剂制备方法和用途 |
| CN119638669A (zh) * | 2023-09-15 | 2025-03-18 | 上海医药集团股份有限公司 | 一种趋化因子受体拮抗剂、药物组合物和应用 |
| WO2025098425A1 (zh) * | 2023-11-09 | 2025-05-15 | 浙江华海药业股份有限公司 | 趋化因子受体调节剂制备方法和用途 |
| WO2025109150A1 (en) | 2023-11-24 | 2025-05-30 | Ludwig-Maximilians-Universität München, In Vertretung Des Freistaates Bayern | The combination of gm-csf and inhibition of ccl22-ccr4 signaling in the treatment of cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| SI0880508T1 (en) | 1996-02-13 | 2003-10-31 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| AU2002354476A1 (en) * | 2001-12-14 | 2003-06-30 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| WO2005082865A1 (ja) * | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| WO2007111227A1 (ja) * | 2006-03-24 | 2007-10-04 | Astellas Pharma Inc. | アシルアミノピペリジン化合物 |
| JP2010208945A (ja) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| KR101048448B1 (ko) * | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| JP2010126496A (ja) * | 2008-11-28 | 2010-06-10 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| WO2010097395A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Pyrazole derivatives used as ccr4 receptor antagonists |
| CN102666545B (zh) * | 2009-10-20 | 2016-04-06 | 塞尔卓姆有限公司 | 作为jak抑制剂的杂环吡唑并嘧啶类似物 |
| EP2560962B1 (en) * | 2010-04-22 | 2015-05-20 | Janssen Pharmaceutica NV | Indazole compounds useful as ketohexokinase inhibitors |
| US9040545B2 (en) * | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| CA2856831C (en) * | 2011-12-01 | 2020-02-18 | Chemocentryx, Inc. | Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists |
| KR102000770B1 (ko) | 2011-12-01 | 2019-07-16 | 케모센트릭스, 인크. | Ｃｃｒ(4) 길항제로서의 치환된 아닐린 |
| WO2014026327A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| WO2016021742A1 (en) * | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| WO2016192083A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10179787B2 (en) | 2016-07-29 | 2019-01-15 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
-
2017
- 2017-07-28 US US15/662,861 patent/US10179787B2/en active Active
- 2017-07-28 ES ES17835338T patent/ES2925564T3/es active Active
- 2017-07-28 KR KR1020197004851A patent/KR102566924B1/ko active Active
- 2017-07-28 NZ NZ750182A patent/NZ750182A/en unknown
- 2017-07-28 RU RU2019105534A patent/RU2768827C2/ru active
- 2017-07-28 JP JP2019526200A patent/JP6985388B2/ja active Active
- 2017-07-28 HU HUE17835338A patent/HUE059242T2/hu unknown
- 2017-07-28 EP EP17835338.9A patent/EP3490565B1/en active Active
- 2017-07-28 SG SG11201900561XA patent/SG11201900561XA/en unknown
- 2017-07-28 AU AU2017302635A patent/AU2017302635B2/en active Active
- 2017-07-28 WO PCT/US2017/044369 patent/WO2018022992A1/en not_active Ceased
- 2017-07-28 MX MX2019001223A patent/MX394691B/es unknown
- 2017-07-28 PL PL17835338.9T patent/PL3490565T3/pl unknown
- 2017-07-28 DK DK17835338.9T patent/DK3490565T3/da active
- 2017-07-28 TW TW106125505A patent/TWI817929B/zh active
- 2017-07-28 IL IL264397A patent/IL264397B2/en unknown
- 2017-07-28 CN CN201780060183.8A patent/CN109789146B/zh active Active
- 2017-07-28 PT PT178353389T patent/PT3490565T/pt unknown
- 2017-07-28 CA CA3032133A patent/CA3032133A1/en active Pending
-
2018
- 2018-11-19 US US16/195,506 patent/US10604526B2/en active Active
-
2019
- 2019-02-14 ZA ZA2019/00961A patent/ZA201900961B/en unknown
-
2020
- 2020-01-28 US US16/775,192 patent/US20200239480A1/en not_active Abandoned
-
2023
- 2023-11-13 US US18/389,182 patent/US20240199620A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3490565T3 (pl) | Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie | |
| IL276295A (en) | Modulators of chemokine receptors and their uses | |
| IL259342B (en) | Modulators of chemokine receptors | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EP3099677A4 (en) | Diaminopyrimidine benzenesulfone derivatives and uses thereof | |
| IL247847B (en) | ror gamma modulator and their use | |
| EP3180332A4 (en) | Difluoropyrrolidines as orexin receptor modulators | |
| IL264514A (en) | Spiro-lactam modulates and uses of the nmda receptor | |
| IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EP3169683A4 (en) | Functionalised and substituted indoles as anti-cancer agents | |
| IL264495B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EP3150578A4 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| EP3166636A4 (en) | Psgl-1 modulators and uses thereof | |
| EP3224261A4 (en) | Opioid receptor modulators | |
| IL254921B (en) | Pyridopyrimidinones and their uses as nmda receptor modulators | |
| GB201520191D0 (en) | T-cell receptor and uses thereof | |
| EP3185873A4 (en) | Pharmaceutical composition and methods | |
| EP3143005A4 (en) | Chemokine cxcr4 and ccr5 receptor modulators and used related thereto | |
| EP3146962A4 (en) | Allisartan isoproxil solid dispersion and pharmaceutical composition thereof | |
| PL3347376T3 (pl) | Nowy receptor IGFR-podobny i jego zastosowania | |
| IL248490A0 (en) | History of cyclics and pharmaceutical preparations that include them | |
| EP3135167A4 (en) | Detachable device, and hinge device employing same | |
| HK40120508A (en) | Opioid receptor modulators | |
| ZA201606656B (en) | Ror-gamma modulators and uses thereof |